CGEN Share Price | Compugen Ltd. Stock Analysis & Recommendation

Q: Is Compugen Ltd. technically bullish or bearish?

As of 22 May 2025, the technical trend has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by daily moving averages indicating a bearish outlook, while weekly MACD and KST show a mildly bullish signal. However, the monthly indicators, including Bollinger Bands and KST, lean towards a bearish stance. The RSI shows no clear signal in both weekly and monthly time frames. Overall, while there are some mildly bullish signals in the weekly data, the prevailing trend remains bearish.

Q: Is Compugen Ltd. overvalued or undervalued?

As of 4 March 2025, the valuation grade for Compugen Ltd. has moved from expensive to risky. The company is currently assessed as overvalued given its negative financial metrics and performance indicators. Key ratios include a Price to Book Value of 2.85, an EV to EBITDA of -4.01, and a Return on Equity (ROE) of -24.77%. In comparison to peers, Compugen Ltd. has a significantly lower P/E ratio of -10.91, while Immunome, Inc. and CARA Therapeutics, Inc. have P/E ratios of -4.55 and -6.24, respectively. This indicates that Compugen is underperforming relative to its peers in the same risky valuation category. Additionally, the company's stock has underperformed against the S&P 500 over the past year, with a return of -17.26% compared to the index's 10.26%, further reinforcing the notion that it is overvalued.

Q: How big is Compugen Ltd.?

Market Cap: As of Jun 18, Compugen Ltd. has a market capitalization of 154.30 million, classified as a Micro Cap.Recent Quarterly Performance: For the latest four quarters, Compugen Ltd. reported net sales of 27.58 million and a net profit of -14.14 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 54.91 million and total assets of 115.00 million.

Q: What does Compugen Ltd. do?

Overview:Compugen Ltd. is a therapeutic discovery company in the Pharmaceuticals & Biotechnology industry, focusing on drug target discovery and the development of therapeutics.Financial Snapshot:Most recent Net Sales: 2 Million (Quarterly Results - Mar 2025) Most recent Net Profit: -7 Million (Quarterly Results - Mar 2025) Market cap: USD 154.30 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.81 Return on Equity: -24.77% Price to Book: 2.70Contact Details:Address: Azrieli Center, 26 Harokmim St. Bldg D, HOLON None: 5885849 Tel: 972 3 7658585 Fax: 972 3 7658555 Website: http://cgen.com/

Q: Should I buy, sell or hold Compugen Ltd.?

Based on the current financial situation of Compugen Ltd., it would be advisable to consider selling your shares. The company has reported very negative results, including a significant decline in net profit and net sales, along with consecutive quarters of negative performance. The pre-tax profit has also seen a drastic fall, and the company is currently operating with a negative EBITDA, which indicates financial instability.Additionally, the stock's performance over the past year has not yielded any returns, despite a rise in profits, suggesting that the market may not have confidence in the company's recovery or growth prospects. Given these factors, holding onto or buying more shares could be risky. Therefore, selling might be the most prudent option at this time.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

146.51 k

Shareholding (Mar 2026)

FII

2.27%

Held by 27 FIIs

DII

97.73%

Held by 4 DIIs

Promoter

0.00%

Is Compugen Ltd. technically bullish or bearish?

25-Jun-2025

As of May 22, 2025, the trend is mildly bearish, with daily moving averages indicating bearishness, weekly indicators showing mild bullishness, and monthly indicators leaning bearish.

View full answer

Is Compugen Ltd. overvalued or undervalued?

25-Jun-2025

As of March 4, 2025, Compugen Ltd. is considered risky and overvalued due to negative financial metrics, including a Price to Book Value of 2.85, an EV to EBITDA of -4.01, and a Return on Equity of -24.77%, alongside a significantly lower P/E ratio of -10.91 compared to peers, and a stock performance of -17.26% over the past year versus the S&P 500's 10.26% return.

View full answer

How big is Compugen Ltd.?

22-Jun-2025

As of Jun 18, Compugen Ltd. has a market capitalization of 154.30 million, with net sales of 27.58 million and a net profit of -14.14 million over the last four quarters.

View full answer

What does Compugen Ltd. do?

22-Jun-2025

Compugen Ltd. is a therapeutic discovery company focused on drug target discovery and developing therapeutics, with a market cap of $154.30 million and recent net sales of $2 million. As of March 2025, it reported a net profit loss of $7 million.

View full answer

Should I buy, sell or hold Compugen Ltd.?

22-Jun-2025

Who are in the management team of Compugen Ltd.?

22-Jun-2025

As of March 2022, the management team of Compugen Ltd. includes Mr. Paul Sekhri (Chairman), Dr. Anat Cohen-Dayag (CEO), and several directors: Dr. Jean-Pierre Bizzari, Mr. Gilead Halevy, Dr. Kinneret Livnat Savitsky, Mr. Eran Perry, and Dr. Michal Preminger. They oversee the company's strategic direction and operations.

View full answer

Compare Compugen Ltd. with Similar Stocks

Carmell Corp.Spruce Biosciences, Inc.Kodiak Sciences, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Positive results in Mar 26

NET SALES(HY) Higher at USD 69.51 MM
NET PROFIT(HY) Higher at USD 49.18 MM
ROCE(HY) Highest at 45.72%

With ROE of 34.40%, it has a very attractive valuation with a 1.88 Price to Book Value

Majority shareholders : Mutual Funds

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 193 Million (Micro Cap)

P/E

5.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.41

Return on Equity

34.40%

Price to Book

1.88

Revenue and Profits:

Net Sales:

2 Million

(Quarterly Results - Mar 2026)

Net Profit:

-8 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-7.37%

6 Months

33.11%

1 Year

21.82%

2 Years

8.06%

3 Years

50.0%

4 Years

16.18%

5 Years

-74.3%

Compugen Ltd. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

105.20%

EBIT Growth (5y)

24.53%

EBIT to Interest (avg)

-26.16

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.81

Sales to Capital Employed (avg)

0.52

Tax Ratio

47.42%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

16.38%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.88

EV to EBIT

1.52

EV to EBITDA

1.52

EV to Capital Employed

-1.13

EV to Sales

0.66

PEG Ratio

0.02

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

34.40%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Dow Theory

Mildly Bullish

OBV

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2026

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 5 Schemes (2.52%)

Foreign Institutions

Held by 27 Foreign Institutions (2.27%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is -96.73% vs 3,442.11% in Dec 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is -113.56% vs 911.43% in Dec 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Dec'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2.20",
          "val2": "67.30",
          "chgp": "-96.73%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-9.00",
          "val2": "56.00",
          "chgp": "-116.07%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-7.70",
          "val2": "56.80",
          "chgp": "-113.56%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-4,143.80%",
          "val2": "832.30%",
          "chgp": "-497.61%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 160.93% vs -16.72% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 348.59% vs 24.47% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "72.80",
          "val2": "27.90",
          "chgp": "160.93%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "31.80",
          "val2": "-14.40",
          "chgp": "320.83%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "35.30",
          "val2": "-14.20",
          "chgp": "348.59%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "430.50%",
          "val2": "-534.40%",
          "chgp": "96.49%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ

Mar'26

Dec'25

Change(%)

Net Sales

2.20

67.30

-96.73%

Operating Profit (PBDIT) excl Other Income

-9.00

56.00

-116.07%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-7.70

56.80

-113.56%

Operating Profit Margin (Excl OI)

-4,143.80%

832.30%

-497.61%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Mar 2026 is -96.73% vs 3,442.11% in Dec 2025

Consolidated Net Profit

QoQ Growth in quarter ended Mar 2026 is -113.56% vs 911.43% in Dec 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

72.80

27.90

160.93%

Operating Profit (PBDIT) excl Other Income

31.80

-14.40

320.83%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

35.30

-14.20

348.59%

Operating Profit Margin (Excl OI)

430.50%

-534.40%

96.49%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 160.93% vs -16.72% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 348.59% vs 24.47% in Dec 2024

All Annual Results

Company CV

About Compugen Ltd.

Compugen Ltd.

Pharmaceuticals & Biotechnology

Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.

Company Coordinates

Company Details

Azrieli Center, 26 Harokmim St. Bldg D , HOLON None : 5885849

Tel: 972 3 7658585

http://cgen.com/

Registrar Details